Medtecs International Corporation (9103) Fair Value & Analysis
Healthcare · TW · Market cap 2.9B TWD
Fair value as of: Jul 21, 2026
From 3 valuation models · updated 20 days ago
Fair value updated Jul 21, 2026, revised from 3.85 TWD to 3.88 TWD (+0.8%) since Jul 12, 2026. Share price +4.6% over the past month.
A solid business, but screening 27% overvalued on our models.
What matters now
- The model range is unusually wide (1.94 TWD to 6.14 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 4.04 TWD – 37.00 TWD · fair‑value band 1.94 TWD – 6.14 TWD · the 5.28 TWD price screens above the 3.88 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Medtecs International Corporation (9103) currently trades at 5.28 TWD, while our model-based Fair Value estimate is 3.88 TWD, implying the stock looks roughly 26.5% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Medtecs International Corporation generated revenue of 79.0M TWD at a net margin of -6.0%. Revenue grew 47.2% year over year. It earns a return on equity of -4.6%. Net debt stands at 6.2M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 1.94 TWD (bear case) to 6.14 TWD (bull case); at 5.28 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 22% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -27%, 9103 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (4.23 TWD) versus Dividend Discount (3.17 TWD). Highest evidence: Gordon GGM (70).
Notify me when 9103 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 54
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Medtecs International Corporation Limited, an integrated healthcare services provider, manufactures and distributes medical consumables for healthcare distributors, pharmaceutical companies, and hospital groups. It operates through Manufacturing, Hospital, and Distribution and Others segments.
Full company description
Medtecs International Corporation Limited, an integrated healthcare services provider, manufactures and distributes medical consumables for healthcare distributors, pharmaceutical companies, and hospital groups. It operates through Manufacturing, Hospital, and Distribution and Others segments. The Manufacturing segment produces and sub-contracts a range of medical consumables, including patients' apparel, disposable surgical masks, boot covers and surgical gowns, underpads, adult diapers, crochet blankets, bed linens, and medical bandages. Its Hospital Services segment offers laundry and leasing services to hospitals that outsource its non-critical functions. The Distribution segment markets Medtecs-branded medical consumables to hospitals, pharmacies, and other end users, as well as through online channels. This segment also supplies other branded medical supplies and equipment comprising wheelchairs, syringes, nebulizers, and blood pressure monitors. In addition, the company manufactures, leases, trades in, and sells woven and knitted medical textile products; provides personal protective equipment, nitrile gloves, garters, and other garment products, as well as logistics and procurement services; trades in hospital textiles and garments, pillow cases, bed sheets, gowns, and other apparel products; sells hygiene products; and engages in subleasing activities. It operates in the Philippines, Singapore, Cambodia, China, Bermuda, Taiwan, Luxembourg, the United States, the United Kingdom, and internationally. Medtecs International Corporation Limited was founded in 1989 and is headquartered in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Medtecs International Corporation reported revenue of 78.4M TWD in FY2025 versus 144M TWD in FY2021, a compound −14.1%/yr. Reported net income was −4.8M TWD in FY2025.
9103 screens 27% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Medtecs International Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medtecs International Corporation (9103) overvalued or undervalued?
What is the fair value of 9103?
What is the quality score of 9103?
What is the revenue of Medtecs International Corporation (9103)?
What is the net profit margin of 9103?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Medtecs International Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.